Before treating certain patients, Daniel J. DeAngelo, MD, JD, of Harvard Medical School and the Dana-Farber Cancer Institute, will council them on the risk of developing neutropenia, which can result in hospitalization or even an intensive care stay.
Before treating certain patients, Daniel J. DeAngelo, MD, JD, of Harvard Medical School and the Dana-Farber Cancer Institute, will council them on the risk of developing neutropenia, which can result in hospitalization or even an intensive care stay.
Neutropenia had first been defined when an analysis of different levels of neutrophils revealed that patients with a neutrophil count of less than 500 had a marked increase in the risk of infection. Here, DeAngelo, who focuses his research on acute myelogenous leukemia, acute lymphoblastic leukemia, and chronic myelogenous leukemia, discusses diagnosing neutropenia in a patient and the associated costs if a patient does develop neutropenia.
AJMC®: How do you diagnose neutropenia? What symptoms are you looking for and what is the neutrophil threshold?
DJD: It’s interesting that patients with myelodysplastic syndrome are often neutropenic but few of them will get infections. So there’s probably a component of being neutropenic—neutrophils of less than 500—and receiving cytotoxic chemotherapy, which may damage the mucosal barrier, which puts patients at risk for developing really the most severe complications of neutropenia, which is febrile neutropenia, which often warrants admission to the hospital, and broad-spectrum antibiotics.
AJMC®: What is the cost of care associated with treating neutropenia?
DJD: Patients with neutropenia are at a risk of infection, sepsis, bacteremia, and the cost is hospitalization, broad-spectrum antibiotics, often anti-fungal therapy. And many patients become profoundly sick with sepsis or sepsis-like syndrome, requiring an intensive care stay.
AJMC®: Are patients often educated in advance of treatment about neutropenia and how serious can it be?
DJD: When I see a patient when I’m administering chemotherapy or a patient who has chronic bone marrow failure, resulting in neutropenia, I always council them and I give them very explicit instructions to call the office or page the on-call physician if they develop a low-grade fever, which I define in Fahrenheit scale of 100.5. And to really seek emergent medical evaluation for a fever of greater than 101.
So I council patients; I always document in my note that patients know they’re at risk of an infection and that any fever may be the result of a life threatening infection.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Uniting to Support Patients With Cancer Beyond Treatment
November 17th 2024Kasey Bond, MPH, of Perlmutter Cancer Center at NYU Langone Health, speaks to why it’s vital to keep patients at the center of all strategic partnerships between academic institutions and community-based oncology practices.
Read More
FDA Approves Danziten for Chronic Myeloid Leukemia Without Mealtime Restrictions
November 14th 2024The FDA has granted approval to Azurity Pharmaceuticals' nilotinib tablets (Danziten), a novel version of the tyrosine kinase inhibitor for chronic myeloid leukemia that can be taken without mealtime restrictions.
Read More
Bridging Cancer Care Gaps and Overcoming Medical Mistrust
November 13th 2024In this clip from our interview with Oscar B. Lahoud, MD, cochair of our Institute for Value-Based Medicine® evening hosted with NYU Langone Health, he addressed medical mistrust in underrepresented communities.
Read More